Annexon (ANNX) Net Income towards Common Stockholders (2019 - 2026)
Annexon's (ANNX) quarterly Net Income towards Common Stockholders came in at -$78.1 million in Q1 2026, down 9.25% year-on-year from -$86.0 million in Q1 2025, and down 61.78% quarter-over-quarter from -$48.3 million in Q4 2025.
Annexon (ANNX) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends
Annexon's Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$78.1 million for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 9.25% year-over-year to -$78.1 million in Q1 2026; TTM through Mar 2026 was -$232.3 million, a 25.9% decrease from a year earlier, with the FY2025 full-year figure at -$208.5 million, down 50.9% from the prior year.
- Net Income towards Common Stockholders eased to -$78.1 million in Q1 2026 per ANNX's latest filing, from -$48.3 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$29.6 million in Q2 2024 and bottomed at -$160.9 million in Q4 2023.
- The 5-year median for Net Income towards Common Stockholders is -$51.0 million (2025), against an average of -$59.2 million.
- Across the five-year window, Net Income towards Common Stockholders slumped 367.93% in 2023 and jumped 69.8% in 2024, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$34.4 million in 2022, then slumped by 367.93% to -$160.9 million in 2023, then soared by 69.8% to -$48.6 million in 2024, then rose by 0.69% to -$48.3 million in 2025, then plunged by 61.78% to -$78.1 million in 2026.
- Per Business Quant, the three latest ANNX Net Income towards Common Stockholders figures stand at -$78.1 million (Q1 2026), -$48.3 million (Q4 2025), and -$54.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Annexon | 1.02 Bn | 1.02 Bn | - | -78.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -78.07 Mn |
| Dec 31, 2025 | -48.26 Mn |
| Sep 30, 2025 | -54.92 Mn |
| Jun 30, 2025 | -51.01 Mn |
| Mar 31, 2025 | -71.46 Mn |
| Dec 31, 2024 | -48.59 Mn |
| Sep 30, 2024 | -34.82 Mn |
| Jun 30, 2024 | -29.61 Mn |
| Mar 31, 2024 | -70.62 Mn |
| Dec 31, 2023 | -160.89 Mn |
| Sep 30, 2023 | -78.77 Mn |
| Jun 30, 2023 | -82.85 Mn |
| Mar 31, 2023 | -54.96 Mn |
| Dec 31, 2022 | -34.38 Mn |
| Sep 30, 2022 | -35.05 Mn |
| Jun 30, 2022 | -37.14 Mn |
| Mar 31, 2022 | -35.37 Mn |
| Dec 31, 2021 | -37.37 Mn |
| Sep 30, 2021 | -35.60 Mn |
| Jun 30, 2021 | -31.29 Mn |